Recombinant human VEGF165b protein is an effective anti-cancer agent in mice
- 30 September 2008
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 44 (13), 1883-1894
- https://doi.org/10.1016/j.ejca.2008.05.027
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in miceBritish Journal of Cancer, 2008
- VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyBritish Journal of Cancer, 2008
- A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2Cellular and Molecular Life Sciences, 2006
- The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at termClinical Science, 2006
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice VariantCancer Research, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat modelJournal of Pharmacy and Pharmacology, 2002
- Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac PerformanceJournal of Cardiovascular Pharmacology, 1996
- Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature, 1992